Investigation of the Cellular Immune Response to Recombinant Fragments of Filamentous Hemagglutinin and Pertactin of<i>Bordetella pertussis</i>in BALB/c Mice

Bakhshaei, Peyman; Kazemi, Mohammad Hossein; Golara, Maryam; Abdolmaleki, Sara; Khosravi-Eghbal, Roya; Khoshnoodi, Jalal; Judaki, Mohammad Ali; Salimi, Vahid; Douraghi, Masoumeh; Jeddi‐Tehrani, Mahmood; Shokri, Fazel

doi:10.1089/jir.2017.0060

Cited by 16 publications

(7 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Synthetic CpG oligodeoxynucleotides (ODNs) that mimic this process have adjuvant capacity, generate strong Th1 responses in mice and humans and are capable of overriding the alum-driven Th2 bias when used in combination with alum [ 188 , 189 , 190 ]. The addition of CpG ODNs to an aP vaccine, either with or without alum, increased anti-PT IgG2a serum antibody titers [ 191 ] and robustly induce IFN-γ-producing splenic T cells [ 192 ]. Ross et al showed that an experimental aP vaccine formulated with CpG alone induced B. pertussis -specific Th1 and Th17 responses, and IgG2 antibody responses in mice [ 16 ].…”

Section: Experimental Vaccinesmentioning

confidence: 99%

Next-Generation Pertussis Vaccines Based on the Induction of Protective T Cells in the Respiratory Tract

Chasaide

Mills

2020

Vaccines

View full text Add to dashboard Cite

Immunization with current acellular pertussis (aP) vaccines protects against severe pertussis, but immunity wanes rapidly after vaccination and these vaccines do not prevent nasal colonization with Bordetella pertussis. Studies in mouse and baboon models have demonstrated that Th1 and Th17 responses are integral to protective immunity induced by previous infection with B. pertussis and immunization with whole cell pertussis (wP) vaccines. Mucosal Th17 cells, IL-17 and secretory IgA (sIgA) are particularly important in generating sustained sterilizing immunity in the nasal cavity. Current aP vaccines induce potent IgG and Th2-skewed T cell responses but are less effective at generating Th1 and Th17 responses and fail to prime respiratory tissue-resident memory T (TRM) cells, that maintain long-term immunity at mucosal sites. In contrast, a live attenuated pertussis vaccine, pertussis outer membrane vesicle (OMV) vaccines or aP vaccines formulated with novel adjuvants do induce cellular immune responses in the respiratory tract, especially when delivered by the intranasal route. An increased understanding of the mechanisms of sustained protective immunity, especially the role of respiratory TRM cells, will facilitate the development of next generation pertussis vaccines that not only protect against pertussis disease, but prevent nasal colonization and transmission of B. pertussis.

show abstract

Section: Experimental Vaccinesmentioning

confidence: 99%

Next-Generation Pertussis Vaccines Based on the Induction of Protective T Cells in the Respiratory Tract

Chasaide

Mills

2020

Vaccines

View full text Add to dashboard Cite

show abstract

“…First, tumor cells must express antigens for T cell recognition and activation (immunogenicity). Then, cancer cells should recruit adjuvant-like danger signals such as damage-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs) to boost the immunogenicity (adjuvanticity) ( 63 , 64 ). Conventional chemotherapies improve the immunogenicity and adjuvanticity of cancer cells by inducing cellular death and stress ( Figure 3 ) ( 65 ).…”

Section: Immunomodulatory Effects Of Chemotherapymentioning

confidence: 99%

Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors

et al. 2022

View full text Add to dashboard Cite

New evidence suggests that the clinical success of chemotherapy is not merely due to tumor cell toxicity but also arises from the restoration of immunosurveillance, which has been immensely neglected in previous preclinical and clinical researches. There is an urgent need for novel insights into molecular mechanisms and regimens that uplift the efficacy of immunotherapy since only a minority of cancer patients are responsive to immune checkpoint inhibitors (ICIs). Recent findings on combination therapy of chemotherapy and ICIs have shown promising results. This strategy increases tumor recognition and elimination by the host immune system while reducing immunosuppression by the tumor microenvironment. Currently, several preclinical studies are investigating molecular mechanisms that give rise to the immunomodulation by chemotherapeutic agents and exploit them in combination therapy with ICIs in order to achieve a synergistic clinical activity. In this review, we summarize studies that exhibit the capacity of conventional chemotherapeutics to elicit anti-tumor immune responses, thereby facilitating anti-tumor activities of the ICIs. In conclusion, combining chemotherapeutics with ICIs appears to be a promising approach for improving cancer treatment outcomes.

show abstract

“…Viral, bacterial, and yeast vectors can also be loaded with genes encoding neoantigens and induce robust immune responses against the tumor (44). These vectors release pathogen-associated molecular patterns (PAMPs) that stimulate the innate and adaptive immune response and increase the infiltration of immune cells into the tumor site (206)(207)(208)(209)(210). Adenoviruses, lentiviruses, retroviruses, and Poxviruses are important viral vectors in vaccine design (211).…”

Section: Cancer Vaccinesmentioning

confidence: 99%

Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?

Lan

Huang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the second leading cause of cancer death in the world. Immunotherapy using monoclonal antibodies, immune-checkpoint inhibitors, adoptive cell therapy, and cancer vaccines has raised great hopes for treating poor prognosis metastatic CRCs that are resistant to the conventional therapies. However, high inter-tumor and intra-tumor heterogeneity hinder the success of immunotherapy in CRC. Patients with a similar tumor phenotype respond differently to the same immunotherapy regimen. Mutation-based classification, molecular subtyping, and immunoscoring of CRCs facilitated the multi-aspect grouping of CRC patients and improved immunotherapy. Personalized immunotherapy using tumor-specific neoantigens provides the opportunity to consider each patient as an independent group deserving of individualized immunotherapy. In the recent decade, the development of sequencing and multi-omics techniques has helped us classify patients more precisely. The expansion of such advanced techniques along with the neoantigen-based immunotherapy could herald a new era in treating heterogeneous tumors such as CRC. In this review article, we provided the latest findings in immunotherapy of CRC. We elaborated on the heterogeneity of CRC patients as a bottleneck of CRC immunotherapy and reviewed the latest advances in personalized immunotherapy to overcome CRC heterogeneity.

show abstract

Investigation of the Cellular Immune Response to Recombinant Fragments of Filamentous Hemagglutinin and Pertactin ofBordetella pertussisin BALB/c Mice

Cited by 16 publications

References 37 publications

Next-Generation Pertussis Vaccines Based on the Induction of Protective T Cells in the Respiratory Tract

Next-Generation Pertussis Vaccines Based on the Induction of Protective T Cells in the Respiratory Tract

Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors

Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?

Contact Info

Product

Resources

About